ATE442148T1 - Kombinationstherapie durch glukoseresorptionshemmer und retinoid x rezeptorenmodulatoren - Google Patents

Kombinationstherapie durch glukoseresorptionshemmer und retinoid x rezeptorenmodulatoren

Info

Publication number: ATE442148T1
Authority: AT; Austria
Prior art keywords: combination therapy; retinoid; receptor modulators; absorption inhibitors; glucose absorption
Prior art date: 2001-04-04

Application number

AT02715273T

Other languages

English (en)

Inventor

Jacqueline Bussolari

Xiaoli Chen

Bruce Conway

Keith Demarest

Hamish Ross

Rafael Severino

Original Assignee

Ortho Mcneil Janssen Pharm

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-04

Filing date

2002-04-03

Publication date

2009-09-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23077475&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE442148(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-04-03 Application filed by Ortho Mcneil Janssen Pharm filed Critical Ortho Mcneil Janssen Pharm

2009-09-15 Application granted granted Critical

2009-09-15 Publication of ATE442148T1 publication Critical patent/ATE442148T1/de

Links

238000002648 combination therapy Methods 0.000 title abstract 2
239000003112 inhibitor Substances 0.000 title abstract 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title 1
102000034527 Retinoid X Receptors Human genes 0.000 title 1
108010038912 Retinoid X Receptors Proteins 0.000 title 1
238000010521 absorption reaction Methods 0.000 title 1
239000008103 glucose Substances 0.000 title 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
230000030558 renal glucose absorption Effects 0.000 abstract 1
208000011580 syndromic disease Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Ophthalmology & Optometry (AREA)
Molecular Biology (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Reproductive Health (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Child & Adolescent Psychology (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Liquid Crystal (AREA)
Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
Laminated Bodies (AREA)

AT02715273T 2001-04-04 2002-04-03 Kombinationstherapie durch glukoseresorptionshemmer und retinoid x rezeptorenmodulatoren ATE442148T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US28147901P	2001-04-04	2001-04-04
PCT/US2002/010542 WO2002080935A1 (en)	2001-04-04	2002-04-03	Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators

Publications (1)

Publication Number	Publication Date
ATE442148T1 true ATE442148T1 (de)	2009-09-15

Family

ID=23077475

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02715273T ATE442148T1 (de)	2001-04-04	2002-04-03	Kombinationstherapie durch glukoseresorptionshemmer und retinoid x rezeptorenmodulatoren

Country Status (11)

Country	Link
US (3)	US6838442B2 (de)
EP (1)	EP1392326B1 (de)
JP (1)	JP4590158B2 (de)
CN (1)	CN100384430C (de)
AT (1)	ATE442148T1 (de)
CA (1)	CA2443325C (de)
DE (1)	DE60233655D1 (de)
ES (1)	ES2331561T3 (de)
MY (1)	MY148432A (de)
TW (1)	TWI345978B (de)
WO (1)	WO2002080935A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR0013671A (pt)	1999-08-31	2003-06-10	Maxia Pharmaceuticals Inc	Derivados heterocìclicos para o tratamento do diabetes e outras doenças
WO2002072009A2 (en)	2001-03-07	2002-09-19	Maxia Pharmaceuticals, Inc.	Heterocyclic derivatives for the treatment of cancer and other proliferative diseases
JP2004523571A (ja)	2001-03-08	2004-08-05	マキシア・ファーマシューティカルズ・インコーポレイテッド	Ｒｘｒ活性化分子
JP4590159B2 (ja)	2001-04-04	2010-12-01	オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド	グルコース再吸収阻害剤およびｐｐａｒモジュレーターを含んで成る併用療法
NZ519403A (en) *	2001-06-21	2005-03-24	Pfizer Prod Inc	Use of insulin in a medicament to reduce weight gain in a diabetic patient who is using exogenous insulin to control blood sugar levels
EP1456187A4 (de) *	2001-11-15	2005-02-09	Incyte San Diego Inc	N-substituierte heterocyclen zur behandlung von hypercholesterinämie, dyslipidämie und anderen metabolischen störungen, krebs und anderen krankheiten
US7102000B2 (en) *	2002-03-08	2006-09-05	Incyte San Diego Inc.	Heterocyclic amide derivatives for the treatment of diabetes and other diseases
US7196108B2 (en) *	2002-03-08	2007-03-27	Incyte San Diego Inc.	Bicyclic heterocycles for the treatment of diabetes and other diseases
DE10258008B4 (de) *	2002-12-12	2006-02-02	Sanofi-Aventis Deutschland Gmbh	Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258007B4 (de) *	2002-12-12	2006-02-09	Sanofi-Aventis Deutschland Gmbh	Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
CA2530228A1 (en) *	2003-06-27	2005-01-06	Dr. Reddy's Research Foundation	Compositions comprising balaglitazone and further antidiabetic compounds
CN1319956C (zh) *	2003-09-12	2007-06-06	深圳市海粤门生物科技开发有限公司	一种噻唑烷二酮的衍生物及其药用制剂的制备方法和应用
US9421175B2 (en)	2004-03-17	2016-08-23	Lars Michael Larsen	Prevention of retinopathy by inhibition of the visual cycle
DE102006028862A1 (de)	2006-06-23	2007-12-27	Merck Patent Gmbh	3-Amino-imidazo[1,2-a]pyridinderivate
DE102007008420A1 (de)	2007-02-21	2008-08-28	Merck Patent Gmbh	Benzimidazolderivate
DE102007048716A1 (de)	2007-10-11	2009-04-23	Merck Patent Gmbh	Imidazo[1,2-a]pyrimidinderivate
ES2541141T3 (es) *	2008-01-31	2015-07-16	Astellas Pharma Inc.	Composición farmacéutica para el tratamiento de las enfermedades del hígado graso
DE102008017590A1 (de)	2008-04-07	2009-10-08	Merck Patent Gmbh	Glucopyranosidderivate
BRPI0913129A2 (pt)	2008-05-22	2016-01-05	Bristol Myers Squibb Co	método para tratamento de hiperuricemia empregando um inibidor de sglt2 e composição contendo o mesmo
MX2011002166A (es)	2008-08-28	2011-04-07	Pfizer	Derivados de dioxa-biciclo[3.2.1]octano-2,3,1-triol.
WO2010141690A2 (en) *	2009-06-04	2010-12-09	Dara Biosciences, Inc.	Indane analogs and use as pharmaceutical agents and process of making
US8163704B2 (en)	2009-10-20	2012-04-24	Novartis Ag	Glycoside derivatives and uses thereof
NZ599945A (en)	2009-11-02	2014-05-30	Pfizer	Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2014113695A1 (en)	2013-01-18	2014-07-24	Cornell University	Methods of treating diseases associated with high fat diet and vitamin a deficiency using retinoic acid receptor agonists
EP2774619B1 (de)	2013-03-04	2016-05-18	BioActive Food GmbH	Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen
EP2944311A1 (de)	2014-05-16	2015-11-18	BioActive Food GmbH	Kombination von biologisch aktiven Substanzen zur Behandlung von hyperglykämischen Erkrankungen
WO2020016335A1 (en)	2018-07-19	2020-01-23	Astrazeneca Ab	Methods of treating hfpef employing dapagliflozin and compositions comprising the same
AU2021202643B2 (en)	2020-07-27	2023-02-02	Astrazeneca Ab	Methods of treating chronic kidney disease with dapagliflozin
PT4188389T (pt)	2020-07-27	2025-10-07	Astrazeneca Ab	Dapagliflozina para utilização em métodos de tratamento de doença renal crónica
WO2022208172A1 (en)	2021-04-01	2022-10-06	Astrazeneca Uk Limited	Systems and methods for managing prediabetes with a gliflozin sodium-glucose cotransport 2 inhibitor pharmaceutical composition
CN118510504A (zh)	2022-01-26	2024-08-16	阿斯利康(瑞典)有限公司	用于在治疗糖尿病前期或降低发展2型糖尿病的风险中使用的达格列净
WO2024259383A2 (en) *	2023-06-14	2024-12-19	President And Fellows Of Harvard College	Ion channel binders and uses thereof
WO2025125513A1 (en)	2023-12-15	2025-06-19	AstraZeneca Ireland Limited	Sglt2 inhibitors and baxdrostat for treating chronic kidney disease and hypertension

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US651003A (en) *	1899-10-12	1900-06-05	Solomon W Bates	Bicycle-pump.
JPH0253573A (ja) *	1988-08-11	1990-02-22	Nippon Riki Kk	ラチェットレンチの製造法
US5731299A (en) *	1992-05-29	1998-03-24	The Procter & Gamble Company	Phosphonosulfonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism
CA2102591C (en) *	1992-11-12	2000-12-26	Kenji Tsujihara	Hypoglycemic agent
US5731292A (en)	1992-11-12	1998-03-24	Tanabe Seiyaku Co., Ltd.	Dihydrochalcone derivatives which are hypoglycemic agents
JP2906978B2 (ja) *	1993-02-25	1999-06-21	田辺製薬株式会社	血糖降下剤
US6046222A (en) *	1993-09-15	2000-04-04	Warner-Lambert Company	Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
JP2847695B2 (ja) *	1994-05-11	1999-01-20	田辺製薬株式会社	血糖降下剤
US5830873A (en) *	1994-05-11	1998-11-03	Tanabe Seiyaku Co., Ltd.	Propiophenone derivative and a process for preparing the same
DK0859608T3 (da)	1995-09-18	2004-06-14	Ligand Pharm Inc	Behandling af NIDDM med RXR-agonister
JP3059088B2 (ja) *	1995-11-07	2000-07-04	田辺製薬株式会社	プロピオフェノン誘導体およびその製法
JP3065235B2 (ja)	1995-11-07	2000-07-17	田辺製薬株式会社	プロピオフェノン誘導体およびその製法
US5732199A (en) *	1996-09-25	1998-03-24	Behavior Tech Computer Corporation	Control method and device of scanner with built-in plug-and-play printer port
TW406086B (en) *	1996-12-26	2000-09-21	Tanabe Seiyaku Co	Propiophenone derivatives and process for preparing the same
JP3055135B2 (ja) *	1996-12-26	2000-06-26	田辺製薬株式会社	プロピオフェノン誘導体及びその製法
US6153632A (en)	1997-02-24	2000-11-28	Rieveley; Robert B.	Method and composition for the treatment of diabetes
EP0975343A1 (de)	1997-06-18	2000-02-02	Smithkline Beecham Plc	Behandlung der diabetes mit thiazolidindione und alpha-glukosidaseinhibitor
JP2000080041A (ja)	1998-03-09	2000-03-21	Tanabe Seiyaku Co Ltd	医薬組成物
TWI249401B (en)	1999-04-14	2006-02-21	Takeda Chemical Industries Ltd	Agent for improving ketosis
AR035016A1 (es)	1999-08-25	2004-04-14	Takeda Chemical Industries Ltd	Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
UA71994C2 (en)	1999-08-31	2005-01-17	Kissei Pharmaceutical	Glucopyranosyloxypyrazole derivatives, a pharmaceutical composition containing these derivatives and intermediate compounds for the preparation thereof
BR0013671A (pt) *	1999-08-31	2003-06-10	Maxia Pharmaceuticals Inc	Derivados heterocìclicos para o tratamento do diabetes e outras doenças
PE20010580A1 (es)	1999-09-03	2001-05-25	Takeda Chemical Industries Ltd	Composicion farmaceutica para tratar la diabetes
JP2001192375A (ja) *	1999-10-29	2001-07-17	Takeda Chem Ind Ltd	オキシイミノアルカン酸誘導体の結晶
AR031078A1 (es)	1999-10-29	2003-09-10	Takeda Pharmaceutical	Compuesto acido (e)-4-[4-(5-metil-2-fenil-4-oxalilmetoxi)benziloxiimino]-4-fenilbutirico cristalino, composicion farmaceutica que lo comprende y su uso para fabricar esta ultima.
ES2225252T3 (es)	1999-11-10	2005-03-16	Takeda Chemical Industries, Ltd.	Compuestos n-heterociclicos de 5 miembros con actividad hipoglucemica e hipolipidemica.
US6555519B2 (en)	2000-03-30	2003-04-29	Bristol-Myers Squibb Company	O-glucosylated benzamide SGLT2 inhibitors and method
US6683056B2 (en) *	2000-03-30	2004-01-27	Bristol-Myers Squibb Company	O-aryl glucoside SGLT2 inhibitors and method
NZ537490A (en) *	2000-10-30	2006-11-30	Ortho Mcneil Pharm Inc	Treatment of diabetes and syndrome X using a sulfamate derivate such as topiramate and metformin
SI1354888T1 (sl)	2000-12-28	2009-10-31	Kissei Pharmaceutical	Glukopiranoziloksipirazolni derivati in njihova uporaba v zdravilih
JP4590159B2 (ja)	2001-04-04	2010-12-01	オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド	グルコース再吸収阻害剤およびｐｐａｒモジュレーターを含んで成る併用療法

2002
- 2002-04-03 CA CA2443325A patent/CA2443325C/en not_active Expired - Lifetime
- 2002-04-03 ES ES02715273T patent/ES2331561T3/es not_active Expired - Lifetime
- 2002-04-03 US US10/115,725 patent/US6838442B2/en not_active Expired - Lifetime
- 2002-04-03 JP JP2002578974A patent/JP4590158B2/ja not_active Expired - Fee Related
- 2002-04-03 AT AT02715273T patent/ATE442148T1/de not_active IP Right Cessation
- 2002-04-03 WO PCT/US2002/010542 patent/WO2002080935A1/en not_active Ceased
- 2002-04-03 DE DE60233655T patent/DE60233655D1/de not_active Expired - Lifetime
- 2002-04-03 EP EP02715273A patent/EP1392326B1/de not_active Expired - Lifetime
- 2002-04-03 CN CNB02810482XA patent/CN100384430C/zh not_active Expired - Lifetime
- 2002-04-04 MY MYPI20021222A patent/MY148432A/en unknown
- 2002-04-04 TW TW091106917A patent/TWI345978B/zh not_active IP Right Cessation
2003
- 2003-02-24 US US10/372,517 patent/US20030195235A1/en not_active Abandoned
2007
- 2007-10-24 US US11/923,187 patent/US8183213B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA2443325C (en)	2011-06-14
CN100384430C (zh)	2008-04-30
TWI345978B (en)	2011-08-01
DE60233655D1 (de)	2009-10-22
US20090075864A1 (en)	2009-03-19
US8183213B2 (en)	2012-05-22
EP1392326B1 (de)	2009-09-09
CN1511038A (zh)	2004-07-07
US20030055091A1 (en)	2003-03-20
EP1392326A1 (de)	2004-03-03
ES2331561T3 (es)	2010-01-08
MY148432A (en)	2013-04-30
CA2443325A1 (en)	2002-10-17
US20030195235A1 (en)	2003-10-16
JP2004529914A (ja)	2004-09-30
WO2002080935A1 (en)	2002-10-17
US6838442B2 (en)	2005-01-04
JP4590158B2 (ja)	2010-12-01

Legal Events

Date	Code	Title	Description
2010-03-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60233655D1 (de)	2009-10-22	R und retinoid x rezeptorenmodulatoren
ATE423559T1 (de)	2009-03-15	Kombinationstherapie durch glukoseresorptionshemmer und ppar modulatoren
PT1333887E (pt)	2006-10-31	Metodo de tratamento de desordens musculares
PL374865A1 (en)	2005-11-14	Treatment of tnf alpha related disorders
MY142777A (en)	2010-12-31	Substituted indole-o-glucosides
UA87991C2 (en)	2009-09-10	Substituted indole-o-glucosides
EA200601555A1 (ru)	2007-02-27	Замещенные индазол-о-глюкозиды
DK1651161T3 (da)	2012-01-30	Farmaceutiske præparater og fremgangsmåder til at fremme sårheling
NO20050607L (no)	2005-02-03	Fremgangsmate og innretning for tildeling av CO
PL371736A1 (en)	2005-06-27	Method for administering glp-1 molecules
SI1427409T1 (sl)	2009-02-28	Postopki za zdravljenje ali preprečevanje vaskularnega vnetja z uporabo zaviralca(-ev) absorpcije sterola
NO20053042L (no)	2005-06-21	Anvendelse av spongosin (2-metoksyadenosin) for behandling av smerte, saerlig hyperalgesi.
DK1097173T3 (da)	2008-09-01	Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler
MY141528A (en)	2010-05-14	Anilinopyrazole derivatives useful for the treatment of diabetes
NO20045554L (no)	2004-12-20	Fremgangsmate for behandling av diabetes
DK1706133T3 (da)	2011-01-17	Fremgangsmåder til beskyttelse mod stråling ved anvendelse af flagellin
PT1051187E (pt)	2004-03-31	Tratamento de linfomas foliculares usando inibidores da via da linfotoxina (lt)
AU2003234425A1 (en)	2003-11-11	Methods for therapeutic treatment of carpal tunnel syndrome
DK1530462T3 (da)	2011-02-14	1-phenyl-2-dimethylaminomethylcyclohexanforbindelser til behandling af depressionssymtomer. smerte og inkontinens
CY1110368T1 (el)	2015-04-29	Συνεργιστικος συνδυασμος ο οποιος περιλαμβανει ροφλουμιλαστη και (r,r)-φορμοτερολη
NO20045344L (no)	2004-12-06	Kombinasjon for behandling av luftveisforstyrrelser
NO20033401D0 (no)	2003-07-30	Kjemiske forbindelser
AU2013204147B2 (en)	2015-09-03	Treatment of TNFalpha related disorders
AU2002330682A1 (en)	2003-03-10	Device for the treatment of persons by music therapy
UA49633A (uk)	2002-09-16	Спосіб лікування діабетичної ретинопатії